Cardiovascular

Latest News

Blood pressure monitor on patient's arm | Image credit: CasanoWa Stutio – stock.adobe.com
Delayed Hypertension Diagnosis Tied to Higher Cardiovascular Risk, Lower Treatment Rates

July 14th 2025

Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year after an elevated blood pressure reading.

Cardiologist listening to patient's heart | Image credit: Space_Cat – stock.adobe.com
40% of Patients With Heart Failure Don’t See Cardiologist Annually, Increasing Risk of Death

June 19th 2025

Gaps in the Coordination of Care for Older Adults With or at Risk for Cardiovascular Disease
Gaps in the Coordination of Care for Older Adults With or at Risk for Cardiovascular Disease

June 3rd 2025

CBD oils and hemp leaves | Image credit: Irina_Evva – stock.adobe.com
CBD-Based Drug Shows No Heart Safety Risks in Patients With CVD or Risk Factors

May 23rd 2025

AJMC
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

May 16th 2025

Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

AJMC Peer Exchange logo
Continuing Medical Education
View All
July 16th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 16th 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology
July 16th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
July 16th 2025

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

1.5 Credits / Cardiology
July 16th 2025

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

1.5 Credits / Cardiology, Rare Diseases
July 16th 2025

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

1.5 Credits / Pulmonology, Cardiology, Rare Diseases

More News

Better Strategies to Reduce Cardiovascular Events
September 16th 2020

Better Strategies to Reduce Cardiovascular Events

Clinical Pathways for Cardiovascular Disease Management
September 16th 2020

Clinical Pathways for Cardiovascular Disease Management

CVD: Cost-Effectiveness Data and Treatment Selection
September 16th 2020

CVD: Cost-Effectiveness Data and Treatment Selection

Cost-Effectiveness Data and Pricing of Icosapent Ethyl
September 16th 2020

Cost-Effectiveness Data and Pricing of Icosapent Ethyl

CV Risk Reduction and Coverage of Therapies
September 16th 2020

CV Risk Reduction and Coverage of Therapies

Cardiovascular Disease Treatment Decisions and Cost
September 16th 2020

Cardiovascular Disease Treatment Decisions and Cost

Cost-Effectiveness and Cardiovascular Risk
September 16th 2020

Cost-Effectiveness and Cardiovascular Risk

Implications for Treating Patients With Icosapent Ethyl
September 16th 2020

Implications for Treating Patients With Icosapent Ethyl

Coronary Plaque Regression and CV Risk
September 16th 2020

Coronary Plaque Regression and CV Risk

Interim Analysis of EVAPORATE
September 16th 2020

Interim Analysis of EVAPORATE

The REDUCE-IT Study and CV Risk
September 16th 2020

The REDUCE-IT Study and CV Risk

Targeting Triglycerides to Reduce CV Risk
September 16th 2020

Targeting Triglycerides to Reduce CV Risk

Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors
September 16th 2020

Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors

PCSK9 Inhibitors and CV Risk
September 16th 2020

PCSK9 Inhibitors and CV Risk

Statin Therapy: Risk for Future CV Events
September 16th 2020

Statin Therapy: Risk for Future CV Events

Statin Therapy for LDL Reduction and CV Risk
September 16th 2020

Statin Therapy for LDL Reduction and CV Risk

Dyslipidemia: Strategies Used to Reduce CV Risk
September 16th 2020

Dyslipidemia: Strategies Used to Reduce CV Risk

Cardiovascular Risk Management
September 16th 2020

Cardiovascular Risk Management

LDL Cholesterol Lowering and CV Risk
September 16th 2020

LDL Cholesterol Lowering and CV Risk

Risk Assessment for Cardiovascular Disease
September 16th 2020

Risk Assessment for Cardiovascular Disease

Economic Burden of Cardiovascular Disease
September 16th 2020

Economic Burden of Cardiovascular Disease

Vascepa Brings 36% Drop in Surgeries to Restore Blood Flow, Results Show
July 25th 2020

Vascepa Brings 36% Drop in Surgeries to Restore Blood Flow, Results Show

Mary Caffrey
Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, presented the latest round of data from REDUCE-IT at the American Society of Preventive Cardiology Virtual Summit 2020 this morning
Reduced Risk of Second Stroke With Ticagrelor Plus Aspirin Than Aspirin Alone
July 17th 2020

Reduced Risk of Second Stroke With Ticagrelor Plus Aspirin Than Aspirin Alone

Mary Caffrey
Transient ischemic attack is a common form of stroke, and 1 in 4 stroke survivors go on to experience a second stroke—most within the first month.
Site Logo
June 16th 2020

VERTIS CV: Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure

Mary Caffrey
A finding that ertugliflozin produced a 30% drop in heart failure hospitalization risk fell outside the study’s primary and secondary end points; here, the drug performed within range of its class, the sodium glucose co-transporter 2 (SGLT2) inhibitors.
Dr Darren K. McGuire Discusses Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in T2D
June 16th 2020

Dr Darren K. McGuire Discusses Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in T2D

Many in the endocrinology community still endorse using metformin first in patients with type 2 diabetes, but that isn’t really necessary any more now that sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are available, said Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center.
Site Logo
June 14th 2020

Is Prevention the Future of SGLT2s? Inzucchi Offers Data That Suggest "Yes"

Mary Caffrey
Yale's Silvio Inzucchi, MD, who has been involved in groundbreaking trials with SGLT2 inhibitors for the past decade, shared data that show patients who did not have type 2 diabetes (T2D) when they started the DAPA-HF trial were 32% less likely to develop the disease if they took dapagliflozin (Farxiga) instead of placebo.
Site Logo
June 13th 2020

Cardiovascular Benefits of Vascepa Greater for Those With Diabetes, New REDUCE-IT Data Show

Mary Caffrey
When it comes to diabetes, lead study author Deepak L. Bhatt, MD, MPH, said clinicians and payers should weigh the considerable costs of what happens when a patient suffers a heart attack or stroke when deciding on a treatment regimen.
Dr Darren K. McGuire Debates SGLT2 Inhibitors and GLP-1 Receptor Agonists as CVD Prime Time Prevention
June 12th 2020

Dr Darren K. McGuire Debates SGLT2 Inhibitors and GLP-1 Receptor Agonists as CVD Prime Time Prevention

In a debate at the American Diabetes Association 80th Scientific Sessions, Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center, will discuss whether sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are ready to be used for primary cardiovascular prevention.
American Heart Association Offers Guidance on Diabetes, Coronary Artery Disease
April 16th 2020

American Heart Association Offers Guidance on Diabetes, Coronary Artery Disease

Gianna Melillo
Recently, it has been shown that the mechanism by which glucose is managed can have a substantial impact on cardiovascular outcomes. For this reason, along with increasing prevalence of type 2 diabetes (T2D), effective, patient-centered management of coronary artery disease (CAD) in patients with diabetes is imperative to optimize patient outcomes, the American Heart Association said.
What We're Reading: Coronavirus-Related Heart Issues; Racial Disparities in COVID-19 Outcomes; Urging Smokers to Quit
April 6th 2020

What We're Reading: Coronavirus-Related Heart Issues; Racial Disparities in COVID-19 Outcomes; Urging Smokers to Quit

AJMC Staff
Coronavirus disease 2019 (COVID-19) was linked with cardiovascaluar issues and cardiac arrest; African Americans were shown to have higher rates of infection and death due to COVID-19; health experts call for smokers to cease use and manufacturers to halt production.
<1
...
456789101112
...
24>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo